TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Change from Baseline on whole brain volume (assessed by brain MRI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Mean Percent Change in Fasting Non-high Density Lipoprotein (HDL) Cholesterol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Proportion of stunning resolved
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of vulnerable plaques in carotid artery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Aqueous Humor Drug Concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Multidimensional Anxiety Scale for Children (MASC 2)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Efficacy of Folate Supplementation for Reducing Negative Symptoms as Measured by the SANS Modified Total
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Urethral catheter related pain/discomfort
Endpoint domain: Adverse events/effects
Primary endpoint: Mean Ocular Itching at Onset of Action
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Ocular Itching at 24 Hours Duration of Action
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum BNP level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Pilot hole and screw trajectory accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Total Surgical Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Skin Closure Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Clinical and laboratory parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Randomized Participants With a Complete Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Conversion to Glaucoma
Endpoint domain: Mortality/survival
Primary endpoint: Blood flow patterns
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Sensitivity and specificity of CLM in diagnosing NERD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Negative predictive value of CLM in diagnosing NERD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Positive predictive value of CLM in diagnosing NERD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Edinburgh Postpartum Depression Scale (EPDS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accumulation of anti-Xa activity in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Removal of anti-Xa activity by filtration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Muscle Mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: change in UP/Cr ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Bone Regeneration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of HUS development
Endpoint domain: Adverse events/effects
Primary endpoint: Recovery from endometrial hyperplasia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Tidal volume (mL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post-operative edema
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Immunogenicity Results After Each Vaccination in Participants 18 to 64 Years of Age
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Immunogenicity Results After Each Vaccination in Participants ≥65 Years of Age
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: In-the-bag stability of intraocular lenses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: number of patients with deterioration
Endpoint domain: Adverse events/effects
Primary endpoint: Change From Baseline in Severe Impairment Battery (SIB)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Clinician's Interview-Based Impression of Change With Caregiver Input (CIBIC-plus)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Percentages of Subjects With Seroconversion or Significant Increase in SRH Area
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentages of Subjects With Haemagglutinin Inhibition (HI) Titers ≥40
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in score of State&Trait version of STAI
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Microbiome shift
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of people who inject drugs (PWIDs) with HCV who were recruited and retained
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Medication adherence to study drug
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Challenges of medication adherence
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Change From Baseline Osteoarthritis (OA) Pain in the Target Knee
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Patients Who Had an Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of histologic core procurement
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Maximum Concentration (Cmax) of Vandetanib and N-desmethyl Vandetanib in Plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time Taken to Reach the Maximum Concentration (Tmax) of Vandetanib and N-desmethyl Vandetanib in Plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Concentration of Vandetanib in Resected Liver Tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Substance craving
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Measures on Likert scales
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Intensity of image artifacts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: rCMRglu
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Recommended Phase-2 Dose (RP2D)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Volatile organic compounds signature
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Electronic signal measured by the electronic nose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to First Postoperative Flatus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Livebirth >20 weeks
Endpoint domain: Mortality/survival
Primary endpoint: Developing glaucoma or progression with glaucoma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Levels of anxiety and depression
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Levels of resilience
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Levels of fear of COVID-19
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Intensity of cervical pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Neurotoxicity Burden
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Leg Press Strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Likelihood of self removal
Endpoint domain: Adverse events/effects
Primary endpoint: Pigmentation of full body, face, trunk and extremities
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Fat free mass at discharge
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Effectiveness evaluation (therapeutic success)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety evaluation (occurrence of complications)
Endpoint domain: Adverse events/effects
Primary endpoint: Intrapartum cardiac complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Postpartum cardiac complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of CT-Detected Lung Nodules by Participant
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Size of CT-Detected Lung Nodules by Participant
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participant Overall Responses as Measured by RECIST Criteria at 12 Months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnosis of tuberculosis (TB) in children
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change in Maximum Noise Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Average Noise Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total perfused small vessel density
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average total number of contrast enhancing lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of the vaccine regimen
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of postoperative atelectasis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Insulin secretory capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Body fat content
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Circulating concentrations of pro-inflammatory cytokines
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Total PANSS score at endpoint versus baseline for non-acute patients transitioned due to lack of efficacy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total PANSS score at endpoint versus baseline for acute patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total PANSS score at endpoint versus baseline for non-acute patients transitioned for other reasons
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Inflammation Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Dose-limiting Toxicity Rate
Endpoint domain: Adverse events/effects
Primary endpoint: Nausea and vomiting classification
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Parkinson's Disease Cognitive Rating Scale (PD-CRS)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Non-Relapse Mortality (NRM)
Endpoint domain: Mortality/survival
Primary endpoint: Prevalence of soil-transmitted helminths
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Intensity of soil-transmitted helminth infections
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Incidence of grade 3 infusion reaction
Endpoint domain: Adverse events/effects
Primary endpoint: Two-year PSA failure rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Time to PSA failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Ottawa Bowel Prep Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in sedentariness
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: admission-free survival
Endpoint domain: Mortality/survival
Primary endpoint: Time to feeding goal achievement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reconstructed Breast Volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Vascular Fibrosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Knowledge of Egyptian Dentists regarding The Hall technique
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Practice of Egyptian Dentists regarding The Hall technique
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Attitude of Egyptian Dentists regarding The Hall technique
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Adverse airway events
Endpoint domain: Adverse events/effects
Primary endpoint: Change in maximal inspiratory pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Complete healing of the target ulcer
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of Oral Habit
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CR/CRi rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Posture angle
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: General posture status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gastric cancer occurrence
Endpoint domain: Mortality/survival
Primary endpoint: Change From Baseline in the Restless Legs Syndrome Rating Scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Percentage of Participants With Improvement on Clinical Global Impression Scale
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in Hoarding Symptom Severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Foot posture
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plantar force variables
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Ejection Fraction (EF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Bi-ventricular Pacing Improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: apparent terminal half-life (t1/2λz)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Participation-Corrected Operative Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Spontaneous Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Incidence of aGVHD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Gastroesophageal reflux disease (GERD) remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: reduction in HBA1c-levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Decrease in viral DNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Visual Analog Pain Score for Mean Maximum Procedural Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline of VO2MAX
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Participation Rates
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Percentage of Participants With Neutrophil Engraftment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Symptom Free Days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to corneal clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total consumption of FVIII (in IU/kg)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: FVIII:C achieved compared to expected levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ECG findings
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Immunological reaction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Fatigue response
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Number of Patients Who Engraft
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: length of non-essential Internet use in hours/week
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: CGI-Improvement
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Body weight and composition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Contrast sensitivity - behavioral
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Contrast sensitivity - electrophysiological
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of subjects with adjudicated Acute Chest Syndrome (ACS)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of subjects with adjudicated severe and/or generalized cutaneous manifestations
Endpoint domain: Adverse events/effects
Primary endpoint: Number of subjects with serious adverse events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With at Least One Treatment Emergent Adverse Event (TEAE) and Serious Adverse Event (SAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Clinically Significant Abnormal Laboratory Values Reported as TEAE
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Peripheral Neuropathy Reported as a TEAE
Endpoint domain: Adverse events/effects
Primary endpoint: Recurrence of depression
Endpoint domain: Adverse events/effects
Primary endpoint: Death within 24 hours
Endpoint domain: Mortality/survival
Primary endpoint: Neurological deterioration within 24 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Proportion of volume reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dermatology Life Quality Index (DLQI) Domain Scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Lymphatic Filariasis-Specific Quality of Life (LFSQQ) Domain Scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: World Health Organization Disability Assessment Schedule 2.0 (WHODAS 2.0) Domain Scores
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change From Baseline on 24-hour Average Systolic Blood Pressure (SBP) at Week 4
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Prostate Volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: progression rate of tumor
Endpoint domain: Mortality/survival
Primary endpoint: maternal SpHb
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: maternal venous hemoglobin measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change From Baseline in Hemoglobin A1C (%) at Week 24
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Participants With One or More Adverse Events (AEs) - Week 0 to Week 54
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants Discontinuing Study Drug Due to An Adverse Event
Endpoint domain: Adverse events/effects
Primary endpoint: Change in AOFAS ankle-hindfoot score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Number of Patients That Achieve Target Intraocular Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Change of Intraocular Pressure Preoperatively vs Postoperatively
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Number of Participants With Complete Response, Partial Response, Progressive Disease and Stable Disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Objective measurement of physical activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Subjective measurement of daily physical activity
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Subjective measurement of physical activity during the past 7 days
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Symptoms of post traumatic stress disorder
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Percentage rate of ST elevation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of participants with residual stones or cholangitis symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: objective response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Time to central nervous system progress confirmed by MRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes